Retatrutide & Tirzepatide | GIP, GLP-1 & Metabolic Research UK

Retatrutide and Tirzepatide

Retatrutide & Tirzepatide are two investigational/therapeutic molecules that have attracted substantial interest in metabolic and obesity research.

Retatrutide (LY3437943) is a triple receptor agonist targeting GIP, GLP-1 and glucagon receptors. Published research has investigated its effects on body weight and metabolic measures.

Tirzepatide (LY3298176) is a GIP and GLP-1 receptor agonist and has been extensively studied in clinical research.

Research is also directly comparing the two molecules. The TRIUMPH-5 phase 3 study is designed to evaluate the efficacy and safety of retatrutide compared with tirzepatide in adults with obesity. The trial has an estimated enrolment of 800 participants and is expected to run through 2026.

Synedica Retatrutide 40mg Pen

Research comparison

Retatrutide’s triple-receptor mechanism differentiates it from tirzepatide’s dual GIP/GLP-1 activity.

Important product information

Do not state that retatrutide and tirzepatide are intended to be administered together unless your manufacturer documentation specifically establishes that formulation and intended use.

Likewise, don’t describe retatrutide as an approved UK medicine. Current research continues to evaluate retatrutide, including phase 3 studies.

Tirzepatide 40mg, GLP-1 weight loss pen injection

These are excellent relevant references for this page.

1. Anchor: retatrutide clinical research

Retatrutide Phase 2 Obesity Trial — 

Retatrutide & Tirzepatide are two important compounds in modern metabolic research. Retatrutide & Tirzepatide have attracted significant scientific interest because of their activity on GIP and GLP-1 pathways. Research into Retatrutide & Tirzepatide continues to examine their potential role in metabolic and obesity-related research.

Retatrutide & Tirzepatide have different receptor profiles, making Retatrutide & Tirzepatide particularly interesting for comparative research. Retatrutide & Tirzepatide are investigated in different clinical and scientific settings, and current evidence continues to develop.

.